Zoetis down -50% over the past year

=== SUMMARY === - Post discusses Zoetis (ZTS), world’s largest animal pharma, down 50% over the past year on pet segment contraction fears. - Author’s thesis: At 13x P/E with 9% EPS growth, and management taking on debt for share buybacks, the stock appears materially undervalued. - Quality assessment: Well-researched DD – provides key valuation multiples, growth rate, and insider capital allocation signal (debt-funded buybacks), though lacks detailed competitive moat analysis. === SENTIMENT === BULLISH === TRADE IDEAS === ZTS - LONG | confidence: 0.70 | sentiment: +0.70 Speaker: u/investorinvestor Thesis: 1. THE FACT: ZTS trades at 13x P/E while delivering 9% EPS growth, and management increased debt by 50% to fund buybacks. 2. THE BRIDGE: The combination of low valuation, positive EPS growth, and aggressive management buybacks (signaling intrinsic value > current price) creates a contrarian value opportunity. 3. THE VERDICT: Buy ZTS as a value play on temporary pet sector headwinds, with management providing a strong signal through leveraged buybacks. 4. RISKS: Continued contraction in the pet segment; macro slowdown in animal health spending; rising debt service costs if rates stay high. Timeframe: medium-term Key Points: - -50% price drop offers deep value entry - 13x P/E with 9% EPS growth is cheap - Debt-funded buybacks signal management conviction - Pet segment risk remains the key overhang - Medium-term catalyst: earnings stabilization or buyback acceleration